{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:57:16Z","timestamp":1781006236684,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107284","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:11:13Z","timestamp":1780027873000},"page":"107284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new HANDling of progressive MS and progressive MS trials"],"prefix":"10.1016","volume":"111","author":[{"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107284_bib0001","article-title":"Composite endpoints to detect treatment effects on MS disability progression. Lessons from phase III trial data","author":"Bovis","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.msard.2026.107284_bib0002","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s13311-023-01415-y","article-title":"Effectiveness of Ocrelizumab in primary progressive Multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY)","volume":"20","author":"Chisari","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107284_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2020.100237","article-title":"Measuring upper limb function in MS: which existing patient-reported outcomes are fit for purpose?","volume":"19","author":"Close","year":"2020","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.msard.2026.107284_bib0004","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1177\/1352458517717811","article-title":"Disease modification in advanced MS: focus on upper limb function","volume":"23","author":"Dubuisson","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107284_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.msard.2017.08.002","article-title":"Validation of an environmentally-friendly and affordable cardboard 9-hole peg test","volume":"17","author":"Dubuisson","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107284_bib0007","unstructured":"FDA prescribing information for OCREVUS, 2022. Genentech."},{"key":"10.1016\/j.msard.2026.107284_bib0008","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(26)00617-3","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study","volume":"407","author":"Giovannoni","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107284_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107284_bib0010","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1474-4422(07)70290-9","article-title":"Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations","volume":"6","author":"Hobart","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107284_bib0011","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2015.02.003","article-title":"On the origin of EDSS","volume":"4","author":"Kurtzke","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107284_bib0012","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107284_bib0013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107284_bib0014","series-title":"Treatment Algorithm For Multiple Sclerosis Disease-Modifying Therapies","year":"2023"},{"key":"10.1016\/j.msard.2026.107284_bib0015","unstructured":"Queen Mary University of London, n.d. Chariot-MS Trial [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT04695080 (accessed 5.21.26)."},{"key":"10.1016\/j.msard.2026.107284_bib0016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40900-024-00586-y","article-title":"Engaging a community to focus on upper limb function in people with multiple sclerosis: the ThinkHand campaign case study","volume":"10","author":"Thomson","year":"2024","journal-title":"Res. Involv. Engagem."},{"key":"10.1016\/j.msard.2026.107284_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105529","article-title":"Under & over: a randomised controlled study to develop an upper limb rehabilitation tool for people with Multiple sclerosis","volume":"85","author":"Thomson","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107284_bib0018","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.neurol.2026.02.155","article-title":"Adaptive trials and new designs","volume":"182","author":"Wade","year":"2026","journal-title":"Rev .Neurol."},{"key":"10.1016\/j.msard.2026.107284_bib0019","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.msard.2015.12.006","article-title":"In memoriam: john F. Kurtzke, MD, FACP, FAAN 1926\u20132015","volume":"5","author":"Wallin","year":"2016","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:58:04Z","timestamp":1781002684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"alternative-id":["S2211034826003202"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107284","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new HANDling of progressive MS and progressive MS trials","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107284"}}